May 06, 2021

Episódio 87 - Insuficiência Cardíaca: Tratamento Ambulatorial

56 minutes

Joanne, Guilherme e João se reúnem com o dr. José Carlos Lucena para falar de Insuficiência Cardíaca! Um tema super prevalente e cheio de clinicagens! Dessa vez com um enfoque na terapia farmacológica ambulatorial. Como ajustar a dose de furosemida? Qual a melhor hora para iniciar o beta bloqueador? Qual o papel das gliflozinas? Isso e muito mais!

Minutagem:

(0:35) Apresentação do Convidado Dr. José Carlos Lucena

(3:45) Diuréticos de alça

(18:00) IECA/BRA

(27:00) Betabloqueador

(36:00) Espironolactona

(40:33) Sacubitril Valsartana

(45:00) Gliflozinas

(51:40) Resumo das drogas

(53:36) Desafio da semana

(53:55) Resposta da semana anterior

(55:30) Salves

Referências:

Vargo, Dennis L., et al. "Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure." Clinical Pharmacology & Therapeutics 57.6 (1995): 601-609.

Rohde, Luis E., et al. "Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial." European heart journal 40.44 (2019): 3605-3612.

Testani, Jeffrey M., et al. "Potential Effects of Aggressive Decongestion during the Treatment of Decompensated Heart Failure on Renal Function and Survival: Insights from the ESCAPE Trial Limited Dataset." Journal of Cardiac Failure 16.8 (2010): S104.

Chaudhry, Sarwat I., et al. "Patterns of weight change preceding hospitalization for heart failure." Circulation 116.14 (2007): 1549.

Gattis, Wendy A., et al. "Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial." Journal of the American College of Cardiology 43.9 (2004): 1534-1541.

Packer, Milton, et al. "The effect of carvedilol on morbidity and mortality in patients with chronic heart failure." New England Journal of Medicine 334.21 (1996): 1349-1355.

Brophy, James M., Lawrence Joseph, and Jean L. Rouleau. "β-Blockers in congestive heart failure: a Bayesian meta-analysis." Annals of internal medicine 134.7 (2001): 550-560.

Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions”. New England Journal of Medicine, vol. 327, no 10, setembro de 1992, p. 685–91.

Effects of Enalapril on Mortality in Severe Congestive Heart Failure”. New England Journal of Medicine, vol. 316, no 23, junho de 1987, p. 1429–35.

Pfeffer, Marc A., et al. “Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both”. New England Journal of Medicine, vol. 349, no 20, novembro de 2003, p. 1893–906.

Granger, Christopher B., et al. “Effects of Candesartan in Patients with Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Alternative Trial”. The Lancet, vol. 362, no 9386, setembro de 2003, p. 772–76.

Nanas John N, et al. “Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study”. Journal of the American College of Cardiology, vol. 36, no 7, dezembro de 2000, p. 2090–95.

McMurray, John J. V., et al. “Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure”. New England Journal of Medicine, vol. 371, no 11, setembro de 2014, p. 993–1004.

...more

View all episodes

By TdC

55 ratings